Navigation Links
AXON's Tau Vaccine Offers Potential for Treating Frontotemporal Dementia Patients
Date:4/3/2017

VIENNA, April 3, 2017 /PRNewswire/ -- AXON Neuroscience announced at the 13th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD2017) that the encouraging clinical trial results of the company's active tau vaccine AADvac1 proved its therapeutic potential in Alzheimer's Disease and Frontotemporal Dementia (FTD). In cooperation with the German FTLD Consortium, AXON Neuroscience is starting a pilot Phase I study in patients suffering from the non-fluent variant of Primary Progressive Aphasia (nfvPPA) – a subgroup of FTD. It is for the first time that nfvPPA patients worldwide will have the opportunity to participate in a clinical program with disease-modifying potential.

Potential to treat Frontotemporal Dementia with Tau Vaccine
Data from AXON's Phase I study in Alzheimer's Disease demonstrates that the antibodies elicited by vaccination with AADvac1 could recognize pathological tau protein in Alzheimer's Disease brains. This data suggests that the antibody response in patients can stop or slow down the progression of the disease.

AXON Neuroscience's symposium called "Frontiers in diagnostics and therapy of human tauopathies" was held on April 1, 2017 at the 13th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD 2017) in Vienna, Austria.
AXON Neuroscience's symposium called "Frontiers in diagnostics and therapy of human tauopathies" was held on April 1, 2017 at the 13th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD 2017) in Vienna, Austria.

During AD/PD 2017, AXON's Medical Director, Matej Ondrus, presented additional analysis of AXON's 18-month Follow-up Study of the Phase I, which directly confirms that the antibodies elicited by vaccination with AADvac1 could recognize pathological tau protein also in Corticobasal Degeneration (CBD) and Progressive Supranuclear Palsy (PSP). This data displays that the antibodies produced by the vaccine target a common denominator of AD and FTD, in both of which tau pathology is the driver of the disease.

Matej Ondrus also noted the encouraging new findings from the study: "In this 96 weeks study we demonstrated that the vaccine is safe and we can detect first signals in the therapeutic efficacy." Norbert Zilka, Chief Science Officer of AXON, added: "We have observed a significant correlation between the amount of specific antibodies in the blood of treated patients and cognitive status. This finding nicely reflects our preclinical data. We are looking forward to confirm these results in the ongoing Phase II study in AD."   

Pilot Phase I Study in nfvPPA - a subgroup of FTD
In the second quarter of 2017, AXON, in cooperation with the German FTLD Consortium, is initiating a pilot Phase I study with its active tau vaccine in nfvPPA patients. Currently, there is no disease-modifying treatment available for this indication.

During AXON's sponsored symposium at AD/PD 2017, Prof. Markus Otto, who is leading the German FTLD Consortium, said: "We are studying FTD patients at the FTLD Consortium for a long time and this is the first time to offer a perspective treatment to them. Finally, we are to accomplish with AXON the big milestone in these indications, where the unmet medical need is exceptionally high."   

Non-fluent variant of Primary Progressive Aphasia (nfvPPA)
The non-fluent variant of Primary Progressive Aphasia is a neurodegenerative disorder from the group of Frontotemporal Dementias, where tau pathology is one of the main drivers of the disease. During the initial phase of the disease, nfvPPA presents with a prominent, isolated language deficit. There is a progressive impairment of language during conversation or through speech. Other cognitive functions and motor problems may be also affected as the disease progresses. 

AXON NEUROSCIENCE
AXON Neuroscience is a clinical-stage biotech company and a global leader in development of tau-immunotherapies. Researchers at AXON Neuroscience have worked extensively on the tau hypothesis for more than 25 years. AXON's focus is to deliver a disease-modifying drug and a diagnostic tool for Alzheimer's Disease and other Frontotemporal Dementias and bring a complex solution for people suffering from the devastating disease.

MEDIA CONTACT
Andrea Becker
AXON Neuroscience
+421-903-576-315
media@axon-neuroscience.eu

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/axons-tau-vaccine-offers-potential-for-treating-frontotemporal-dementia-patients-300433342.html


'/>"/>
SOURCE AXON Neuroscience
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Hilleman Laboratories Signs MoU With NICED, ICMR to Develop Shigella Vaccine
2. Animal Vaccines Market Expected to Reach $9,159 Million by 2022 - Allied Market Research
3. Stellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine Technology
4. FDA Grants Orphan Drug Designation to CSRAs DynPort Vaccine Company for Plague Vaccine
5. NanoBio Receives SBIR Grant For Genital Herpes Vaccine
6. New Access to Vaccines Index Reveals First Landscape of Vaccine Company Actions to Improve Immunisation Coverage
7. Global Anti-Infective Vaccine Market - Forecast to Grow 5.88% by 2021 - Driven by Rising Technological Development in Vaccine Industry - Research and Markets
8. Global Vaccine Contract Manufacturing Market Report 2017-2027
9. Protein Sciences and Partnership for Influenza Vaccine Introduction (PIVI) Team Up to Combat the Flu in Mongolia
10. Sanarias PfSPZ Vaccine Confers Significant Protection Against Natural Malaria infections in Mali
11. Expanded Vaccine offering for PharmaJet Needle-free Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... April 19, 2017 Cardiology devices segment is anticipated ... The Cardiology Devices segment is likely to create ... Mn in 2018 over 2017. By the end of 2027, ... close to US$ 700 Mn, expanding at a CAGR of ... the Asia Pacific reprocessed medical devices ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... and which He does not. Yisrayl says with so many titles and names for ... but he says with a little Scripture, backed with a lot of research, the truth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA is ... Côté has 20+ years of experience within the beauty industry, ranging from marketing, ... array of high-end cosmetic brands, retail brands and outlets in Canada and New ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... advanced nutraceutical supplements, through its Nova Skin Sciences division, recently announced the launch ... a moisturizer with the power of an anti-aging concentrate. , Anogeissus ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different movies ... as the host of the “Informed” series. The program focuses on many important issues ... focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, ...
(Date:4/28/2017)... ... ... Christie Medical Holdings, Inc. , with its market-leading vein finder ... a leader in infusion therapy and pain management. , Intravenous (IV) therapy plays ... patients receiving a peripheral IV catheter as part of their treatment plan. Many hospitals ...
Breaking Medicine News(10 mins):